Clinical trial · Observational
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand
NCT01130961CI-TRIAL-00004000completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.
Secondary outcomes (3)
- measure
- Time to maximum response
- timeFrame
- Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx.
- measure
- Overall survival
- timeFrame
- time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx.
- measure
- Prevalence of EGFR & KRAS mutation from laboratory result
- timeFrame
- During Jan 2004- Dec 2008 or 5 years approx.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosed as having lung cancer based on histological/cytological findings * Admitted to the hospital between January 2004 and December 2008 * Treated with gefitinib for at least 3 months Exclusion Criteria: * Involvement in the planning and/or conduct of the study * Participation in another clinical study during the last 3 months
References
Publications (0)
Data not yet available
No reference posted for this study.